Skip to main content
Top
Published in: International Journal of Clinical Oncology 4/2015

01-08-2015 | Original Article

Is mucinous adenocarcinoma of the endometrium a risk factor for lymph node involvement? A multicenter case–control study

Authors: Kemal Gungorduk, Aykut Ozdemir, Ibrahim Egemen Ertas, Ilker Selcuk, Ulas Solmaz, Emre Ozgu, Emre Mat, Mehmet Gokcu, Tuba Karadeniz, Serap Akbay, Muzaffer Sanci, Mehmet Mutlu Meydanli, Duygu Ayaz, Tayfun Gungor

Published in: International Journal of Clinical Oncology | Issue 4/2015

Login to get access

Abstract

Purpose

The purpose of this multicenter case–control study was to compare the demographic and clinical characteristics of patients with mucinous adenocarcinoma of the endometrium (MAE) and endometrioid endometrial carcinoma (EEC).

Methods

A retrospective review of two cancer registry databases in Turkey was conducted to identify patients diagnosed with MAE between January 1996 and December 2012. Each patient was matched with a control EEC patient by age and tumor grade. Cases and controls were compared in terms of known risk factors for lymph node metastasis, disease-free survival (DFS), and overall survival (OS).

Results

The analysis included 112 patients with MAE and 112 with EEC. No significant difference in baseline characteristics was evident between the two groups. Lymphovascular space invasion, deep myometrial invasion, cervical involvement, and tumor diameter did not differ significantly between the mucinous and endometrioid cases. Multivariate analysis confirmed that only mucinous histology (OR 2.2, 95 % CI 1.1–4.5; P = 0.02) was an independent predictor of lymph node involvement. Although the median DFS and OS tended to be better in the endometrioid group, the differences were not statistically significant. Routine appendectomy was performed in 52 (46.2 %) patients with MAE. No mucinous tumor of the appendix was identified.

Conclusion

Routine appendectomy is not necessary when the appendix is grossly normal at the time of surgery for MAE. Although the DFS and OS of EEC and MAE patients were similar, the risk of nodal metastasis in MAE patients was greater than that in ECC patients, and we thus suggest to perform retroperitoneal lymphadenectomy (both pelvic and para-aortic) for patients with MAE during the initial operation.
Literature
2.
go back to reference Ross JC, Eifel PJ, Cox RS et al (1983) Primary mucinous adenocarcinoma of the endometrium. A clinicopathologic and histochemical study. Am J Surg Pathol 7:715–729PubMedCrossRef Ross JC, Eifel PJ, Cox RS et al (1983) Primary mucinous adenocarcinoma of the endometrium. A clinicopathologic and histochemical study. Am J Surg Pathol 7:715–729PubMedCrossRef
3.
go back to reference Trimble CL, Kauderer J, Zaino R et al (2006) Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 106:812–819PubMedCrossRef Trimble CL, Kauderer J, Zaino R et al (2006) Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 106:812–819PubMedCrossRef
4.
go back to reference Ambros RA, Sherman ME, Zahn CM et al (1995) Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 26:1260–1267PubMedCrossRef Ambros RA, Sherman ME, Zahn CM et al (1995) Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 26:1260–1267PubMedCrossRef
5.
go back to reference Kurman RJ, Kaminski PF, Norris HJ (1985) The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer 56:403–412PubMedCrossRef Kurman RJ, Kaminski PF, Norris HJ (1985) The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer 56:403–412PubMedCrossRef
6.
go back to reference Sutton G, Kavanagh J, Wolfson A et al (2005) Corpus: mesenchymal tumors. In: Hoskins WJ, Perez CA, Young RC, Barakat RR, Markman M, Randall ME (eds) Principles and practice of gynecologic oncology, 4th edn. Lippincott, Philadelphia, pp 873–894 Sutton G, Kavanagh J, Wolfson A et al (2005) Corpus: mesenchymal tumors. In: Hoskins WJ, Perez CA, Young RC, Barakat RR, Markman M, Randall ME (eds) Principles and practice of gynecologic oncology, 4th edn. Lippincott, Philadelphia, pp 873–894
7.
go back to reference Hacker NF (2005) Uterine cancer. In: Berek JS, Hacker NF (eds) Practical gynecologic oncology, 5th edn. Lippincott, Philadelphia, pp 396–442 Hacker NF (2005) Uterine cancer. In: Berek JS, Hacker NF (eds) Practical gynecologic oncology, 5th edn. Lippincott, Philadelphia, pp 396–442
8.
go back to reference Reed N, Green JA, Gershenson DM et al (2011) Rare and uncommon gynecological cancers, 1st edn. Springer, Berlin, pp 181–182CrossRef Reed N, Green JA, Gershenson DM et al (2011) Rare and uncommon gynecological cancers, 1st edn. Springer, Berlin, pp 181–182CrossRef
9.
go back to reference Musa F, Huang M, Adams B et al (2012) Mucinous histology is a risk factor for nodal metastases in endometrial cancer. Gynecol Oncol 125:541–545PubMedCrossRef Musa F, Huang M, Adams B et al (2012) Mucinous histology is a risk factor for nodal metastases in endometrial cancer. Gynecol Oncol 125:541–545PubMedCrossRef
10.
go back to reference Galic V, Schiavone MB, Herzog TJ et al (2013) Prognostic significance of mucinous differentiation of endometrioid adenocarcinoma of the endometrium. Cancer Invest 31:500–504PubMedCentralPubMedCrossRef Galic V, Schiavone MB, Herzog TJ et al (2013) Prognostic significance of mucinous differentiation of endometrioid adenocarcinoma of the endometrium. Cancer Invest 31:500–504PubMedCentralPubMedCrossRef
11.
go back to reference Kurman RJ, Carcangiu ML, Herrington CS, et al (2014) WHO classification of tumors of female reproductive organs, 4th edn. World Health Organization Kurman RJ, Carcangiu ML, Herrington CS, et al (2014) WHO classification of tumors of female reproductive organs, 4th edn. World Health Organization
12.
go back to reference Murray SK, Young RH, Scully RE (2003) Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinoma: a study of their frequency, associated diagnostic problems, and prognostic significance. Int J Gynecol Pathol 22:324–333PubMedCrossRef Murray SK, Young RH, Scully RE (2003) Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinoma: a study of their frequency, associated diagnostic problems, and prognostic significance. Int J Gynecol Pathol 22:324–333PubMedCrossRef
13.
go back to reference Todo Y, Okamoto K, Hayashi M et al (2007) A validation study of a scoring system to estimate the risk of lymph node metastasis for patients with endometrial cancer for tailoring the indication of lymphadenectomy. Gynecol Oncol 104:623–628PubMedCrossRef Todo Y, Okamoto K, Hayashi M et al (2007) A validation study of a scoring system to estimate the risk of lymph node metastasis for patients with endometrial cancer for tailoring the indication of lymphadenectomy. Gynecol Oncol 104:623–628PubMedCrossRef
14.
go back to reference Todo Y, Sakuragi N, Nishida R et al (2003) Combined use of magnetic resonance imaging, CA 125 assay, histologic type, and histologic grade in the prediction of lymph node metastasis in endometrial carcinoma. Am J Obstet Gynecol 188:1265–1272PubMedCrossRef Todo Y, Sakuragi N, Nishida R et al (2003) Combined use of magnetic resonance imaging, CA 125 assay, histologic type, and histologic grade in the prediction of lymph node metastasis in endometrial carcinoma. Am J Obstet Gynecol 188:1265–1272PubMedCrossRef
15.
go back to reference Lee KB, Ki KD, Lee JM et al (2009) The risk of lymph node metastasis based on myometrial invasion and tumor grade in endometrioid uterine cancers: a multicenter, retrospective Korean study. Ann Surg Oncol 16:2882–2887PubMedCrossRef Lee KB, Ki KD, Lee JM et al (2009) The risk of lymph node metastasis based on myometrial invasion and tumor grade in endometrioid uterine cancers: a multicenter, retrospective Korean study. Ann Surg Oncol 16:2882–2887PubMedCrossRef
16.
go back to reference Kang S, Kang WD, Chung HH et al (2012) Preoperative identification of a low-risk group for lymph node metastasis in endometrial cancer: a Korean gynecologic oncology group study. J Clin Oncol 30:1329–1334PubMedCrossRef Kang S, Kang WD, Chung HH et al (2012) Preoperative identification of a low-risk group for lymph node metastasis in endometrial cancer: a Korean gynecologic oncology group study. J Clin Oncol 30:1329–1334PubMedCrossRef
17.
go back to reference AlHilli MM, Podratz KC, Dowdy SC et al (2013) Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer. Gynecol Oncol 131:103–108PubMedCrossRef AlHilli MM, Podratz KC, Dowdy SC et al (2013) Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer. Gynecol Oncol 131:103–108PubMedCrossRef
18.
go back to reference Bogani G, Dowdy SC, Cliby WA et al (2014) Role of pelvic and para-aortic lymphadenectomy in endometrial cancer: current evidence. J Obstet Gynaecol Res 40:301–311PubMedCentralPubMedCrossRef Bogani G, Dowdy SC, Cliby WA et al (2014) Role of pelvic and para-aortic lymphadenectomy in endometrial cancer: current evidence. J Obstet Gynaecol Res 40:301–311PubMedCentralPubMedCrossRef
19.
go back to reference Di Saia PJ, Creasman WT (2012) Clinical gynecologic oncology, 8th edn. pp 141–174 Di Saia PJ, Creasman WT (2012) Clinical gynecologic oncology, 8th edn. pp 141–174
20.
go back to reference Rauh-Hain JA, Vargas RJ, Clemmer J et al (2014) Mucinous adenocarcinoma of the endometrium compared with endometrioid endometrial cancer: a SEER analysis. Am J Clin Oncol (Epub ahead of print) Rauh-Hain JA, Vargas RJ, Clemmer J et al (2014) Mucinous adenocarcinoma of the endometrium compared with endometrioid endometrial cancer: a SEER analysis. Am J Clin Oncol (Epub ahead of print)
21.
go back to reference Addison AB, Miller K, Hammouch D et al (2012) Appendiceal metastasis 10 years following ‘curative’ resection for low-grade primary endometrial carcinoma. BMJ Case Rep. pii:bcr1020114895 Addison AB, Miller K, Hammouch D et al (2012) Appendiceal metastasis 10 years following ‘curative’ resection for low-grade primary endometrial carcinoma. BMJ Case Rep. pii:bcr1020114895
22.
go back to reference Dilek S, Dilek U, Dede M et al (2006) The role of omentectomy and appendectomy during the surgical staging of clinical stage I endometrial cancer. Int J Gynecol Cancer 16:795–798PubMedCrossRef Dilek S, Dilek U, Dede M et al (2006) The role of omentectomy and appendectomy during the surgical staging of clinical stage I endometrial cancer. Int J Gynecol Cancer 16:795–798PubMedCrossRef
23.
go back to reference Ozdal B, Unlu BS, Yalcin HR et al (2013) Role of omentectomy and appendectomy in surgical staging of endometrioid endometrial cancer. Eur J Gynaecol Oncol 34:322–324PubMed Ozdal B, Unlu BS, Yalcin HR et al (2013) Role of omentectomy and appendectomy in surgical staging of endometrioid endometrial cancer. Eur J Gynaecol Oncol 34:322–324PubMed
Metadata
Title
Is mucinous adenocarcinoma of the endometrium a risk factor for lymph node involvement? A multicenter case–control study
Authors
Kemal Gungorduk
Aykut Ozdemir
Ibrahim Egemen Ertas
Ilker Selcuk
Ulas Solmaz
Emre Ozgu
Emre Mat
Mehmet Gokcu
Tuba Karadeniz
Serap Akbay
Muzaffer Sanci
Mehmet Mutlu Meydanli
Duygu Ayaz
Tayfun Gungor
Publication date
01-08-2015
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 4/2015
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-014-0767-2

Other articles of this Issue 4/2015

International Journal of Clinical Oncology 4/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine